Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Shannon S Zhang"'
Autor:
Misako Nagasaka, Shannon S. Zhang, Yasmine Baca, Joanne Xiu, Jorge Nieva, Ari Vanderwalde, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Luis E. Raez, Stephen V. Liu, Sai-Hong Ignatius Ou
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence of ROS1 fusions to assess if more ROS1+ patients
Externí odkaz:
https://doaj.org/article/05a3d80854dc433ca5dd01303b8437af
Autor:
Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100546- (2023)
Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on
Externí odkaz:
https://doaj.org/article/4a17b716e5554aaa9e42589db4af6e82
Autor:
Shannon S. Zhang, MD, Alexa B. Schrock, PhD, Misako Nagasaka, MD PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100453- (2023)
Externí odkaz:
https://doaj.org/article/42bf59772e3b4a79b0a1df9d44054573
Autor:
Shannon S. Zhang, MD, Jessica K. Lee, MSc, Hanna Tukachinsky, PhD, Alexa B. Schrock, PhD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100387- (2022)
Introduction: Germline CHEK2 mutations are rare and have not been associated with increased risk of NSCLC. Methods: We identified two sequential primary NSCLCs harboring distinct actionable driver alterations (EGFR E746 _S752 delinsV and CD74-ROS1) i
Externí odkaz:
https://doaj.org/article/e5774861fb6d4b509b5508a9a6e29a18
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100358- (2022)
Externí odkaz:
https://doaj.org/article/5463b1ef6cc74b928dc0626719febbf0
Autor:
Sai-Hong Ignatius Ou, MD, PhD, Joanne Xiu, PhD, Misako Nagasaka, MD, Bing Xia, MD, Shannon S. Zhang, MD, Qing Zhang, PhD, Jeffrey J. Swensen, PhD, David Spetzler, MS, PhD, MBA, Wolfgang Michael Korn, MD, Viola W. Zhu, MD, PhD, Stephen V. Liu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100132- (2021)
Introduction: A novel CD74-NRG2α fusion has recently been identified in NSCLC. We surveyed a large tumor database comprehensively profiled by whole transcriptome sequencing to investigate the incidence and distribution of NRG2 fusions among various
Externí odkaz:
https://doaj.org/article/ac0c0482fe5145d4bdb2310e09e643cc
Publikováno v:
Lung Cancer: Targets and Therapy.
Shannon S Zhang,1 Alexandria Lee,1 Misako Nagasaka1,2 1University of California Irvine School of Medicine, Orange, CA, USA; 2St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, University of California Irvine S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1020c0b9aaf72adec411406e770b064a
https://www.dovepress.com/codebreak-200-sotorasib-has-not-broken-the-krasg12c-enigma-code-peer-reviewed-fulltext-article-LCTT
https://www.dovepress.com/codebreak-200-sotorasib-has-not-broken-the-krasg12c-enigma-code-peer-reviewed-fulltext-article-LCTT
Autor:
Misako Nagasaka, Shannon S. Zhang
Publikováno v:
Lung Cancer: Targets and Therapy
Mutations in codon 12 of KRAS have been identified in 13% of non-small cell lung cancer patients. Developing targeted therapies against KRASG12C mutation has proven to be challenging due to the abundance of GTP in the cytoplasm, rapid hydrolysis of G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60cbd6df0b65b2c0154cedbe4b7b2b22
http://europepmc.org/articles/PMC8504654
http://europepmc.org/articles/PMC8504654
Autor:
Sai-Hong Ignatius Ou, Yanfei Gao, Viola W. Zhu, Kenneth A. Bauer, Joseph J. Zhao, Nicholas Syn, Shannon S. Zhang, Misako Nagasaka
Publikováno v:
Lung Cancer. 157:147-155
INTRODUCTION Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d820b90eec25aa7e022169f291734e5a
https://doi.org/10.1016/j.lungcan.2021.05.019
https://doi.org/10.1016/j.lungcan.2021.05.019
Autor:
Joanne Xiu, Jian Zhang, Viola W. Zhu, Sai-Hong Ignatius Ou, Shannon S. Zhang, Jeffrey Swensen
Publikováno v:
Journal of Thoracic Oncology. 16:e51-e54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02a6e02d9c49680f4d3633b2d45fab32
https://doi.org/10.1016/j.jtho.2021.03.006
https://doi.org/10.1016/j.jtho.2021.03.006